📊 ETON Key Takeaways
Is ETON a Good Investment? Thesis Analysis
Eton Pharmaceuticals demonstrates strong revenue growth of 104.9% YoY and positive free cash flow of $10.2M, indicating improving operational scale and cash generation. However, the company remains unprofitable with negative net income of -$4.6M and operating losses, while carrying significant debt of $21.8M that exceeds available cash reserves, presenting execution and solvency risks.
Why Buy ETON? Key Strengths
- Revenue growth of 104.9% YoY demonstrates strong top-line expansion
- Healthy gross margin of 53.5% indicates pricing power and favorable product mix
- Positive free cash flow of $10.2M (12.7% FCF margin) shows cash generation capability
- Current ratio of 1.57x and quick ratio of 1.17x indicate adequate short-term liquidity
ETON Investment Risks to Consider
- Company is unprofitable with net loss of -$4.6M and operating margin of -1.1%
- Negative interest coverage ratio of -0.2x indicates inability to cover debt service from operating income
- Long-term debt of $21.8M exceeds cash position of $25.9M, creating leverage risk
- Diluted EPS is negative at -$0.23, reflecting shareholder value destruction
- Operating losses persist despite significant revenue growth, suggesting operational inefficiencies
Key Metrics to Watch
- Path to operating profitability and timeline to positive net income
- Operating cash flow sustainability as revenue scales
- Debt reduction progress and leverage ratio trends
- Gross margin stability as product mix and manufacturing scale evolve
- Cash burn rate relative to cash reserves and runway
ETON Financial Metrics
💡 AI Analyst Insight
Eton Pharmaceuticals, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
ETON Profitability Ratios
ETON vs Healthcare Sector
How Eton Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is ETON Overvalued or Undervalued?
Based on fundamental analysis, Eton Pharmaceuticals, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
ETON Balance Sheet & Liquidity
ETON 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Eton Pharmaceuticals, Inc.'s revenue has grown significantly by 266% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.04 indicates the company is currently unprofitable.
ETON Growth Metrics (YoY)
ETON Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $10.3M | $627.0K | $0.02 |
| Q2 2025 | $9.1M | -$2.6M | N/A |
| Q1 2025 | $8.0M | -$811.0K | N/A |
| Q3 2024 | $7.0M | -$579.0K | $-0.02 |
| Q2 2024 | $9.1M | $1.9M | $0.07 |
| Q1 2024 | $5.3M | -$811.0K | $-0.03 |
| Q3 2023 | $3.2M | -$579.0K | $-0.02 |
| Q2 2023 | $7.4M | -$1.6M | $-0.06 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ETON Capital Allocation
ETON SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Eton Pharmaceuticals, Inc. (CIK: 0001710340)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ETON
What is the AI rating for ETON?
Eton Pharmaceuticals, Inc. (ETON) has an AI rating of HOLD with 62% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ETON's key strengths?
Claude: Revenue growth of 104.9% YoY demonstrates strong top-line expansion. Healthy gross margin of 53.5% indicates pricing power and favorable product mix.
What are the risks of investing in ETON?
Claude: Company is unprofitable with net loss of -$4.6M and operating margin of -1.1%. Negative interest coverage ratio of -0.2x indicates inability to cover debt service from operating income.
What is ETON's revenue and growth?
Eton Pharmaceuticals, Inc. reported revenue of $80.0M.
Does ETON pay dividends?
Eton Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find ETON SEC filings?
Official SEC filings for Eton Pharmaceuticals, Inc. (CIK: 0001710340) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ETON's EPS?
Eton Pharmaceuticals, Inc. has a diluted EPS of $-0.23.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ETON a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, Eton Pharmaceuticals, Inc. has a HOLD rating with 62% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ETON stock overvalued or undervalued?
Valuation metrics for ETON: ROE of -17.6% (sector avg: 15%), net margin of -5.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ETON stock in 2026?
Our dual AI analysis gives Eton Pharmaceuticals, Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ETON's free cash flow?
Eton Pharmaceuticals, Inc.'s operating cash flow is $10.5M, with capital expenditures of $333.0K. FCF margin is 12.7%.
How does ETON compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -5.8% (avg: 12%), ROE -17.6% (avg: 15%), current ratio 1.57 (avg: 2).